Clinical Trials

MainTitle

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.

This study has been terminated
Sponsor
RFS Pharma, LLC


Information provided by (Responsible Party)
RFS Pharma, LLC
ClinicalTrials.gov Identifier
NCT01737359

First received: November 27, 2012
Last updated: November 4, 2014
Last Verified: March 2013
History of Changes
Purpose

Purpose

This is a double-blind Phase 2a study to test the safety and efficacy of an investigational HIV drug, amdoxovir (300 mg or 500 mg twice daily) compared with tenofovir DF 300 mg once daily in HIV-1 infected antiretroviral therapy-experienced subjects who are currently failing antiretroviral therapy. There are three treatment groups (N=45). Subjects will be randomized to receive either amdoxovir 300 mg twice daily (n=15) or amdoxovir 500 mg twice daily (n=15) or tenofovir DF 300 mg once daily (n=15); each in combination with zidovudine 300 mg twice daily.

The study will assess initially amdoxovir (300 mg or 500 mg twice daily) or tenofovir DF 300 mg once daily, both in combination zidovudine 300 mg twice daily plus failing third drug, but then with lopinavir/ritonavir (400 mg/100 mg twice daily) after Week 2. Subjects who received amdoxovir (300 mg or 500 mg twice daily) and benefited from the drug may choose to enroll in the 36-week open-label study.

Condition Intervention Phase
Human Immunodeficiency Virus Infection

Drug : amdoxovir 300 mg bid
Drug : amdoxovir 500 mg bid
Drug : tenofovir DF 300 mg qd
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIa, Randomized, Double-blind, Active-controlled, 12-week Study of Amdoxovir (Two Doses) Versus Tenofovir DF, in Combination With Zidovudine in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.

Further study details as provided by RFS Pharma, LLC:

Primary Outcome Measures

  • HIV-1 viral load [ Time Frame: change from baseline to Week 2 ]
  • Safety and Tolerability- Incidence of adverse events and laboratory abnormalities [ Time Frame: number and frequency from baseline through Week 12 ]
Secondary Outcome Measures:
  • HIV-1 viral load [ Time Frame: change from baseline to Weeks 4, 8 and 12 ]
  • Changes in Immunologic Function (CD4 cell counts) [ Time Frame: changes from baseline to Weeks 4, 8 and 12 ]

Enrollment: 2
Study Start Date: December 2012
Study Completion Date: March 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: amdoxovir 300 mg bid
in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
Drug: amdoxovir 300 mg bid

2 x 150 mg capsules bid

Other Name:
  • DAPD
  • AMDX

Experimental: amdoxovir 500 mg bid
in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
Drug: amdoxovir 500 mg bid

2 x 250 mg capsules bid

Other Name:
  • DAPD
  • AMDX

Active Comparator: tenofovir DF 300 mg qd
in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
Drug: tenofovir DF 300 mg qd

1 x 300 mg tablet once daily

Other Name: Viread
Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • Male or female ≥ 18 years old with HIV-1 RNA ≥ 2,000 copies/mL and currently failing therapy.
  • Has M184I/V mutation in addition to 0-2 thymidine analog mutations (TAMs) at screening.
  • Agree to be abstinent or use two reliable forms of contraception (for females) and one form for men when participating in sexual activity that could result in pregnancy.


Exclusion Criteria:
  • Current or recent (last 30 days of study entry) AIDS defining diseases.
  • Genotypic resistance testing at screening indicating K65R, L74V, Q151M mutation.
  • Prior exposure to lopinavir/ritonavir or amdoxovir.
  • Impaired hepatic function (ALT > 5 x ULN).
  • Women who are pregnant or breast feeding.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01737359

Locations

Argentina
Research Site
Rosario, Santa Fe, Argentina, S2000CXP
Research Site
Rosario, Santa Fe, Argentina, S2000PBJ
Research Site
Buenos Aires, Argentina, C1141ACG
Research Site
Buenos Aires, Argentina, C1202ABB
Research Site
Buenos Aires, Argentina, C1405CKC
Research Site
Buenos Aires, Argentina, C1426EGR

Sponsors and Collaborators

RFS Pharma, LLC

Investigators

Study Director: Luz Pascual, MD MPH RFS Pharma
More Information

More Information


Responsible Party: RFS Pharma, LLC  
ClinicalTrials.gov Identifier: NCT01737359   History of Changes  
Other Study ID Numbers: RFSP-AMDX-2010  
Study First Received: November 27, 2012  
Last Updated: November 4, 2014  

Keywords provided by RFS Pharma, LLC:

amdoxovir
zidovudine
tenofovir DF
HIV
HAART
antiretroviral

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Virus Diseases
Tenofovir
Zidovudine

ClinicalTrials.gov processed this data on December 15, 2017
This information is provided by ClinicalTrials.gov.